Bihua Chen
CIK 1599214 · Chairperson and CEO · last filed 2026-01-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$552.49M
Companies
22
Total Filings
43
Lifetime Open-Market Net
$446.78M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HLXC | Chairperson and CEO | 497,500 | $10.35 | $5.15M | $16.00M | 2 | 2026-01-28 |
| EYPT | 10%+ Owner | 8,265,000 | $13.03 | $107.69M | $234.19M | 5 | 2025-12-08 |
| MLTX | 10%+ Owner | 1,994,173 | $18.69 | $37.27M | -$154.25M | 6 | 2025-10-01 |
| BBOT | Director | 4,681,126 | $7.75 | $36.28M | $0 | 1 | 2025-08-13 |
| OKUR | 0 | $4.20 | $0 | -$20.18M | 1 | 2025-05-19 | |
| AARD | 800,189 | $3.90 | $3.12M | $6.00M | 1 | 2025-02-19 | |
| BridgeBio Oncology Therapeutics, Inc. (HLXB) Delisted | CEO and Chairperson | — | $9.90 | — | $0 | 1 | 2025-02-10 |
| DRUG | 10%+ Owner | 1,059,331 | $60.95 | $64.57M | $17.70M | 2 | 2024-11-06 |
| IMRX | 10%+ Owner | 3,294,173 | $4.19 | $13.80M | -$15.64M | 2 | 2024-04-03 |
| CRBP | 10%+ Owner | 1,475,000 | $8.19 | $12.08M | $70.09M | 2 | 2024-02-06 |
| Ambrx Biopharma Inc. (AMAM) Delisted | 10%+ Owner | 68,714,590 | $28.00 | $1.92B | $78.50M | 1 | 2023-09-19 |
| BMEA | Director | 3,570,872 | $1.17 | $4.18M | $0 | 1 | 2023-06-16 |
| ERAS | Director | 10,813,246 | $14.05 | $151.93M | $8.67M | 3 | 2022-12-21 |
| PYXS | Director | 668,854 | $1.76 | $1.18M | $28.80M | 1 | 2021-10-15 |
| BCAB | Director | 2,292,060 | $3.86 | $8.85M | $57.60M | 1 | 2020-12-22 |
| OLMA | Director | 3,270,544 | $9.87 | $32.28M | $40.38M | 1 | 2020-11-23 |
| MoonLake Immunotherapeutics (HLXA) Delisted | CEO and Chairman | 430,000 | $13.25 | $5.70M | $4.30M | 1 | 2020-10-22 |
| RNA | Director | 2,214,545 | $12.37 | $27.39M | $21.60M | 1 | 2020-06-18 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | 3,122,367 | $76.01 | $237.33M | $14.40M | 3 | 2019-08-12 |
| Axonics, Inc. (AXNX) Delisted | Director | 599,999 | $70.98 | $42.59M | $8.00M | 1 | 2018-11-02 |
| KNSA | Director | 900,443 | $51.89 | $46.72M | $5.00M | 1 | 2018-05-31 |
| KINETA, INC./DE (PTI) Delisted | Director | 3,782,726 | — | — | $25.62M | 4 | 2016-12-14 |
Recent Filings · Page 3 of 5
43 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-09-19 | Ambrx Biopharma Inc. (AMAM) Delisted | Buy (P) | +8,610,952 | $78.50M | EDGAR |
| 2023-07-05 | MLTX | Buy (P) | +800,000 | $40.00M | EDGAR |
| 2023-06-28 | MLTX | Buy (P) | +450,000 | $20.54M | EDGAR |
| 2023-06-16 | BMEA | Grant (A) | — | $0 | EDGAR |
| 2023-03-22 | MLTX | Buy (P) | +827,100 | $16.77M | EDGAR |
| 2022-12-21 | ERAS | Buy (P) | +1,230,768 | $8.00M | EDGAR |
| 2022-06-24 | ERAS | Grant (A) | — | $0 | EDGAR |
| 2022-04-07 | MLTX | Mixed | +5,635,000 | $28.50M | EDGAR |
| 2021-10-15 | PYXS | Mixed | +4,475,416 | $28.80M | EDGAR |
| 2021-08-10 | ERAS | Mixed | — | $667.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.